• Targeted therapies for bone regeneration

    We are commercializing a small molecule-based osteoinductive platform technology to develop bone growth products that activate a novel molecular pathway.


    Discovered serendipitously, Zetagen'sTM products have the potential to transform the treatment of bone-related injuries, procedures and diseases to deliver better outcomes for patients, doctors and payors.


    A Serendipitous

    An accidental injection led to the identification of a novel molecular pathway that has the ability to address several unmet clinical needs. After multiple years of research, the ZetagenTM team has characterized the pathway’s novel mechanism of action.
    By controlling cellular division using this novel target, ZetagenTM has the potential to apply the benefits of this technology to several different areas of patient need.
  • Technology


    Initial data indicate this novel pathway has the potential to offer a suite of advantages not observed by other products on market, including:

    Bone Growth

    Initial data show bone generation better than biologic growth factors


    Inhibition of cancer growth via a known p21 mechanism


    Down-regulation of osteoclasts reduces bone destruction

    Small Molecule-Based

    Our products will utilize small molecule components that are significantly more cost-effective to manufacture relative to biologic comparators

    Safe Components

    Components of our products have well-established clinical safety profiles

    New Populations

    The technology has the potential for wider use compared to existing therapies due to its unique safety profile


    Our Science

    A novel pathway for bone growth


    PDF 1.9 mb



    We believe in identifying and pursuing optimal therapeutic solutions - no matter how unconventional - by building a learning organization that maximizes outcomes for people, investors and society.

    Joe Loy


    Joe is a proven leader with a distinguished career in building and leading teams in rapid growth organizations within the spine & orthopedic industries. Recently, he was the Executive V.P., Sales for Life Spine. Prior to that, Joe was the Vice President of Sales for CoAlign and steered their acquisition by Stryker Spine. His first “Start-up” was NuVasive as their 5th hire in sales, held multiple positions of increasing responsibility including Senior Group Director, as sales grew from zero to +$750M during his 11+year tenure. Joe was the National Sales Mgr. for Pfizer / Leibinger, acquired by Stryker, and started his medical device career with U.S. Surgical. He serves as an Advisor & Board of Directors for a variety of orthopedic & spinal implant companies.

    Bryan Margulies, PhD

    CSO and Cofounder

    Dr. Margulies was formerly an assistant professor of orthopedics, cell biology and pharmacology at SUNY-Upstate. His research focuses on stem cell modulation to promote bone formation in all practice areas including bone sarcoma. He obtained his PhD, MS and BS in bioengineering from Syracuse University and trained at the University of Pennsylvania in the College of Veterinary Medicine. Dr. Margulies was an NIH NRSA Fellow, a Mazess Student Fellow and has over 25 publications.

    Nikhil Thakur, MD

    Cofounder and Board Director

    Dr. Thakur is the Director of the Spine Center at Lawrence General Hospital, a Harvard affiliate. He specializes in adult spine reconstructive surgery and has over a decade of orthopedic surgical experience. He has won multiple awards for his orthopedic research and has over 25 publications. Dr. Thakur received his MD from Geisel School of Medicine at Dartmouth and completed his fellowship training in trauma from Brown University and in spine surgery from Emory University.

  • Supporters

    We are grateful for the support we have received to date from several groups including:

  • Contact Us

    Thanks for visiting ZetagenTM. If you are interested in our work and would like to keep track of our progress, please send us a note.